Table 1.
Baseline clinical characteristics of patients with and without adverse event
| Total population (n = 1096) | Without event (n = 955) | With event (n = 141) | P value | |
|---|---|---|---|---|
| Age, years | 59.47 ± 9.86 | 59.77 ± 9.89 | 57.40 ± 9.45 | 0.008 |
| Sex, male, n (%) | 766 (69.9) | 659 (69.0) | 107 (75.9) | 0.118 |
| BMI, kg/m2 | 25.90 ± 3.44 | 25.79 ± 3.44 | 26.67 ± 3.38 | 0.004 |
| SBP, mmHg | 130.17 ± 17.17 | 130.34 ± 17.35 | 129.05 ± 15.92 | 0.407 |
| DBP, mmHg | 77.43 ± 10.84 | 77.37 ± 10.96 | 77.86 ± 10.03 | 0.615 |
| Smoking, n (%) | 528 (48.2) | 458 (48) | 70 (49.6) | 0.776 |
| Medical history, n (%) | ||||
| Hypertension | 664 (60.6) | 588 (51.6) | 76 (53.9) | 0.099 |
| Dyslipidemia | 784 (71.5) | 690 (72.3) | 94 (66.7) | 0.203 |
| Prior PCI | 295 (26.9) | 251 (26.3) | 44 (31.2) | 0.259 |
| Laboratory results | ||||
| TG, mmol/L | 1.53 ± 1.12 | 1.44 ± 0.97 | 2.12 ± 1.73 | < 0.001 |
| TC, mmol/L | 4.11 ± 1.04 | 4.09 ± 1.02 | 4.20 ± 1.21 | 0.227 |
| LDL-C, mmol/L | 2.41 ± 0.89 | 2.40 ± 0.87 | 2.48 ± 1.00 | 0.353 |
| HDL-C, mmol/L | 1.17 ± 0.27 | 1.18 ± 0.28 | 1.06 ± 0.23 | < 0.001 |
| AIP | 0.06 ± 0.28 | 0.04 ± 0.27 | 0.25 ± 0.26 | < 0.001 |
| CRP, mg/L | 2.41 ± 4.33 | 2.38 ± 4.27 | 2.60 ± 4.73 | 0.581 |
| Cr, mg/dL | 71.25 ± 14.98 | 71.16 ± 15.05 | 71.90 ± 14.50 | 0.583 |
| eGFR, mL/(min * 1.73 m2 | 95.43 ± 12.79 | 95.24 ± 12.76 | 96.71 ± 13.00 | 0.203 |
| SUA, µmol/L | 350.84 ± 86.07 | 348.71 ± 85.47 | 365.23 ± 88.99 | 0.033 |
| FBG, mmol/L | 5.93 ± 1.37 | 5.92 ± 1.37 | 5.97 ± 1.37 | 0.680 |
| HbA1c, % | 5.99 ± 0.22 | 5.99 ± 0.22 | 5.96 ± 0.21 | 0.067 |
| Pre-admission medication, n (%) | ||||
| Antiplatelet therapy | 1094 (99.8) | 953 (99.8) | 141 (100.0) | 1 |
| Statins | 1091 (99.5) | 950 (99.5) | 141 (100.0) | 0.848 |
| ACEI | 148 (13.5) | 125 (13.1) | 23 (16.3) | 0.361 |
| ARB | 802 (73.2) | 688 (72.0) | 114 (80.9) | 0.036 |
| nitrate medication | 1011 (92.2) | 883 (92.5) | 128 (90.8) | 0.598 |
| β-blocker | 878 (80.1) | 759 (79.5) | 119 (84.4) | 0.210 |
| Angiographic data | Total population (n = 427) | Without event (n = 366) | With event (n = 61) | |
| Target vessel territory, n (%) | ||||
| LM | 33 (7.7) | 31 (8.5) | 2 (3.3) | 0.251 |
| LAD | 338 (79.2) | 291 (79.5) | 47 (77.0) | 0.789 |
| LCX | 230 (53.9) | 199 (54.5) | 31 (50.8) | 0.707 |
| RCA | 254 (59.5) | 212 (57.9) | 42 (68.9) | 0.142 |
| SYNTAX score | 12.74 ± 7.55 | 12.92 ± 7.61 | 11.66 ± 7.19 | 0.229 |
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; PCI: percutaneous coronary intervention; TG: triglyceride; TC: total cholesterol; LDL-C: low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol; AIP: atherogenic index of plasma; CRP: C-reactive protein; Cr: creatinine; eGFR: estimated glomerular filtration rate; SUA: serum uric acid; FBG: fasting blood-glucose; HbA1c: glycosylated hemoglobin A1c; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; LM: left main artery; LAD: left anterior descending artery; LCX: left circumflex artery; RCA: right coronary artery; SYNTAX: synergy between PCI with taxus and cardiac surgery